A new diagnostic test that would help many women with breast cancer avoid debilitating chemotherapy will not be made available to public patients because it is too expensive.
The National Centre for Pharmacoeconomics (NCPE)s aid the test should not be made available to public patients, and gave the high price of the test as the reason for this.
The new gene test was hailed as a breakthrough in breast cancer diagnosis by cancer specialists.
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team